anagrelide
(TVWRQCIPWUCNMI-UHFFFAOYSA-N)
Structure
- SMILES
- O=C1NC2=Nc3c(CN2C1)c(Cl)c(cc3)Cl.Cl
- Molecular Formula:
- C10H8Cl3N3O
- Molecular Weight:
- 292.549
- Log P:
- 2.4306
- Hydrogen Bond Acceptor:
- 4
- Hydrogen Bond Donor:
- 2
- TPSA:
- 44.7
- CAS Number(s):
- 58579-51-4
Synonym(s)
1.
anagrelide
2.
6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
3.
Agrelin
4.
Agrylin
5.
BL 4162A
6.
anagrelide hydrochloride
7.
imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Myelofibrosis | FAERS: 19 | US FAERS | |
| 2 | MYELODYSPLASTIC SYNDROME | FAERS: 18 | US FAERS | |
| 3 | Palpitations | FAERS: 18 | US FAERS | |
| 4 | Headache | FAERS: 14 | US FAERS | |
| 5 | Cerebrovascular accident | FAERS: 8 | US FAERS | |
| 6 | Tachycardia | FAERS: 8 | US FAERS | |
| 7 | Acute myocardial infarction | FAERS: 7 | US FAERS | |
| 8 | Cardiac Arrest | FAERS: 7 | US FAERS | |
| 9 | Cerebral Infarction | FAERS: 7 | US FAERS | |
| 10 | Dizziness | FAERS: 7 | US FAERS | |
| 11 | Pulmonary Embolism | FAERS: 7 | US FAERS | |
| 12 | Atrial Fibrillation | FAERS: 6 | US FAERS | |
| 13 | Drug exposure during pregnancy | FAERS: 6 | US FAERS | |
| 14 | Pulmonary Hypertension | FAERS: 6 | US FAERS | |
| 15 | Splenomegaly | FAERS: 5 | US FAERS | |
| 16 | Weight decreased | FAERS: 5 | US FAERS | |
| 17 | Chest Pain | FAERS: 4 | US FAERS | |
| 18 | Epistaxis | FAERS: 4 | US FAERS | |
| 19 | Myocardial Infarction | FAERS: 4 | US FAERS | |
| 20 | Sudden death | FAERS: 4 | US FAERS | |
| 21 | Vertigo | FAERS: 4 | US FAERS | |
| 22 | Acute Coronary Syndrome | FAERS: 3 | US FAERS | |
| 23 | Angina Pectoris | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 24 | Asthenia | FAERS: 3 | US FAERS | |
| 25 | Blood potassium increased | FAERS: 3 | US FAERS | |
| 26 | Deep Vein Thrombosis | FAERS: 3 | US FAERS | |
| 27 | Embolism | FAERS: 3 | US FAERS | |
| 28 | Hypotension | FAERS: 3 | US FAERS | |
| 29 | Malaise | FAERS: 3 | US FAERS | |
| 30 | Pulmonary Fibrosis | FAERS: 3 | US FAERS | |
| 31 | Thrombophlebitis | FAERS: 3 | US FAERS | |
| 32 | Ventricular Fibrillation | FAERS: 3 | US FAERS | |
| 33 | Adverse event | FAERS: 2 | US FAERS | |
| 34 | Atrial thrombosis | FAERS: 2 | US FAERS | |
| 35 | Blood erythropoietin increased | FAERS: 2 | US FAERS | |
| 36 | Brain natriuretic peptide increased | FAERS: 2 | US FAERS | |
| 37 | Complex partial seizures | FAERS: 2 | US FAERS | |
| 38 | Coronary Artery Disease | FAERS: 2 | US FAERS | |
| 39 | Drug abuse | FAERS: 2 | US FAERS | |
| 40 | Drug diversion | FAERS: 2 | US FAERS | |
| 41 | Drug ineffective | FAERS: 2 | US FAERS | |
| 42 | Fatigue | FAERS: 2 | US FAERS | |
| 43 | Hypertensive crisis | FAERS: 2 | US FAERS | |
| 44 | Leukocytosis | FAERS: 2 | US FAERS | |
| 45 | Multiple Sclerosis | FAERS: 2 | US FAERS | |
| 46 | Myocarditis | FAERS: 2 | US FAERS | |
| 47 | Nephrosclerosis | FAERS: 2 | US FAERS | |
| 48 | No adverse event | FAERS: 2 | US FAERS | |
| 49 | Pancreatitis | FAERS: 2 | US FAERS | |
| 50 | Pericarditis | FAERS: 2 | US FAERS | |
| 51 | Pregnancy | FAERS: 2 | US FAERS | |
| 52 | Radial nerve palsy | FAERS: 2 | US FAERS | |
| 53 | Respiratory Failure | FAERS: 2 | US FAERS | |
| 54 | Reticulocyte count decreased | FAERS: 2 | US FAERS | |
| 55 | Right ventricular failure | FAERS: 2 | US FAERS | |
| 56 | Sinus Arrhythmia | FAERS: 2 | US FAERS | |
| 57 | Swelling | FAERS: 2 | US FAERS | |
| 58 | Syncope | FAERS: 2 | US FAERS | |
| 59 | Thrombocytopenia | FAERS: 2 | US FAERS | |
| 60 | Thrombosis | FAERS: 2 | US FAERS | |
| 61 | Unevaluable event | FAERS: 2 | US FAERS | |
| 62 | Urticaria | FAERS: 2 | US FAERS | |
| 63 | Vasculitis | FAERS: 2 | US FAERS | |
| 64 | Visual Impairment | FAERS: 2 | US FAERS | |
| 65 | Abdominal Compartment Syndrome | FAERS: 1 | US FAERS | |
| 66 | Abdominal Pain | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 67 | Acanthosis Nigricans | FAERS: 1 | US FAERS | |
| 68 | Accidental exposure to product by child | FAERS: 1 | US FAERS | |
| 69 | Activities of daily living impaired | FAERS: 1 | US FAERS | |
| 70 | Antiphospholipid Syndrome | FAERS: 1 | US FAERS | |
| 71 | Anxiety | FAERS: 1 | US FAERS | |
| 72 | Apallic syndrome | FAERS: 1 | US FAERS | |
| 73 | Aphasia | FAERS: 1 | US FAERS | |
| 74 | Ascites | FAERS: 1 | US FAERS | |
| 75 | Atrial Flutter | FAERS: 1 | US FAERS | |
| 76 | Autoimmune hepatitis | FAERS: 1 | US FAERS | |
| 77 | Blood creatinine increased | FAERS: 1 | US FAERS | |
| 78 | Blood human chorionic gonadotropin increased | FAERS: 1 | US FAERS | |
| 79 | Bone marrow depression | FAERS: 1 | US FAERS | |
| 80 | Bone pain | FAERS: 1 | US FAERS | |
| 81 | Bronchitis | FAERS: 1 | US FAERS | |
| 82 | Budd-Chiari Syndrome | FAERS: 1 | US FAERS | |
| 83 | Cardiac Death | FAERS: 1 | US FAERS | |
| 84 | Cardiac Tamponade | FAERS: 1 | US FAERS | |
| 85 | Cardiotoxicity | FAERS: 1 | US FAERS | |
| 86 | Cauda Equina Syndrome | FAERS: 1 | US FAERS | |
| 87 | Cervix carcinoma | FAERS: 1 | US FAERS | |
| 88 | Colon adenoma | FAERS: 1 | US FAERS | |
| 89 | Congenital absence of vertebra | FAERS: 1 | US FAERS | |
| 90 | Craniofacial fracture | FAERS: 1 | US FAERS | |
| 91 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 92 | Dermatitis Herpetiformis | FAERS: 1 | US FAERS | |
| 93 | Dermatitis | FAERS: 1 | US FAERS | |
| 94 | Disease Progression | FAERS: 1 | US FAERS | |
| 95 | Disease recurrence | FAERS: 1 | US FAERS | |
| 96 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 97 | Drug dose omission | FAERS: 1 | US FAERS | |
| 98 | Dyspepsia | FAERS: 1 | US FAERS | |
| 99 | Dysphonia | FAERS: 1 | US FAERS | |
| 100 | Dysplasia | FAERS: 1 | US FAERS | |
| 101 | Dysuria | FAERS: 1 | US FAERS | |
| 102 | Endothelial dysfunction | FAERS: 1 | US FAERS | |
| 103 | Epilepsy | FAERS: 1 | US FAERS | |
| 104 | Erectile dysfunction | FAERS: 1 | US FAERS | |
| 105 | Erysipelas | FAERS: 1 | US FAERS | |
| 106 | Excessive skin | FAERS: 1 | US FAERS | |
| 107 | Expired product administered | FAERS: 1 | US FAERS | |
| 108 | Eye pain | FAERS: 1 | US FAERS | |
| 109 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 110 | Fibrosis | FAERS: 1 | US FAERS | |
| 111 | Fracture | FAERS: 1 | US FAERS | |
| 112 | Gamma-Glutamyltransferase Increased | FAERS: 1 | US FAERS | |
| 113 | General physical health deterioration | FAERS: 1 | US FAERS | |
| 114 | Glioblastoma | FAERS: 1 | US FAERS | |
| 115 | Glomerulonephritis | FAERS: 1 | US FAERS | |
| 116 | Hepatectomy | FAERS: 1 | US FAERS | |
| 117 | Hepatitis | FAERS: 1 | US FAERS | |
| 118 | Hepatomegaly | FAERS: 1 | US FAERS | |
| 119 | Hepatotoxicity | FAERS: 1 | US FAERS | |
| 120 | Hypersensitivity | FAERS: 1 | US FAERS | |
| 121 | Hypoxia | FAERS: 1 | US FAERS | |
| 122 | Hysterectomy | FAERS: 1 | US FAERS | |
| 123 | Intestinal Obstruction | FAERS: 1 | US FAERS | |
| 124 | Intracranial artery dissection | FAERS: 1 | US FAERS | |
| 125 | Left Ventricular Hypertrophy | FAERS: 1 | US FAERS | |
| 126 | Lethargy | FAERS: 1 | US FAERS | |
| 127 | Lobar Pneumonia | FAERS: 1 | US FAERS | |
| 128 | Lung consolidation | FAERS: 1 | US FAERS | |
| 129 | Lymphoma | FAERS: 1 | US FAERS | |
| 130 | Myalgia | FAERS: 1 | US FAERS | |
| 131 | Myelitis | FAERS: 1 | US FAERS | |
| 132 | Myelocytosis | FAERS: 1 | US FAERS | |
| 133 | Myeloid Metaplasia | FAERS: 1 | US FAERS | |
| 134 | Nephritic syndrome | FAERS: 1 | US FAERS | |
| 135 | Nephritis | FAERS: 1 | US FAERS | |
| 136 | Nephrotic Syndrome | FAERS: 1 | US FAERS | |
| 137 | Overdose | FAERS: 1 | US FAERS | |
| 138 | Pain | FAERS: 1 | US FAERS | |
| 139 | Pancytopenia | FAERS: 1 | US FAERS | |
| 140 | Paranoia | FAERS: 1 | US FAERS | |
| 141 | Patent ductus arteriosus | FAERS: 1 | US FAERS | |
| 142 | Performance status decreased | FAERS: 1 | US FAERS | |
| 143 | Pericardial effusion | FAERS: 1 | US FAERS | |
| 144 | Peripheral swelling | FAERS: 1 | US FAERS | |
| 145 | Pharmaceutical product complaint | FAERS: 1 | US FAERS | |
| 146 | Photophobia | FAERS: 1 | US FAERS | |
| 147 | Platelet count abnormal | FAERS: 1 | US FAERS | |
| 148 | Pleuritic pain | FAERS: 1 | US FAERS | |
| 149 | Pneumonitis | FAERS: 1 | US FAERS | |
| 150 | Polyserositis | FAERS: 1 | US FAERS | |
| 151 | Portal Hypertension | FAERS: 1 | US FAERS | |
| 152 | Presyncope | FAERS: 1 | US FAERS | |
| 153 | Primary Myelofibrosis | FAERS: 1 | US FAERS | |
| 154 | Product quality issue | FAERS: 1 | US FAERS | |
| 155 | Product use in unapproved indication | FAERS: 1 | US FAERS | |
| 156 | Product use issue | FAERS: 1 | US FAERS | |
| 157 | Proteinuria | FAERS: 1 | US FAERS | |
| 158 | Pulmonary arterial hypertension | FAERS: 1 | US FAERS | |
| 159 | Renal tubular acidosis | FAERS: 1 | US FAERS | |
| 160 | Restrictive cardiomyopathy | FAERS: 1 | US FAERS | |
| 161 | Retroperitoneal fibrosis | FAERS: 1 | US FAERS | |
| 162 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 163 | Sepsis | FAERS: 1 | US FAERS | |
| 164 | Skin Ulcer | FAERS: 1 | US FAERS | |
| 165 | Skin necrosis | FAERS: 1 | US FAERS | |
| 166 | Splenic Infarction | FAERS: 1 | US FAERS | |
| 167 | Supraventricular tachycardia | FAERS: 1 | US FAERS | |
| 168 | Temporal Arteritis | FAERS: 1 | US FAERS | |
| 169 | Therapeutic response unexpected | FAERS: 1 | US FAERS | |
| 170 | Therapeutic response unexpected with drug substitution | FAERS: 1 | US FAERS | |
| 171 | Thrombotic stroke | FAERS: 1 | US FAERS | |
| 172 | Transmission of drug via semen | FAERS: 1 | US FAERS | |
| 173 | Traumatic fracture | FAERS: 1 | US FAERS | |
| 174 | Vitiligo | FAERS: 1 | US FAERS | |
| 175 | Wheelchair user | FAERS: 1 | US FAERS | |
| 176 | White blood cell count decreased | FAERS: 1 | US FAERS | |
| 177 | Wrong drug administered | FAERS: 1 | US FAERS | |
| 178 | Wrong technique in drug usage process | FAERS: 1 | US FAERS | |
| 179 | nervous system disorder | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.